Assessment of platelet aspirin responsiveness in Turkish Population with PFA-100, serum thromboxane B2, soluble CD40 ligand and soluble P-Selectin

Saka, Bülent; Genç, Sema Yılmaz; Eroğlu, Hacer; Akpınar, Timur Selçuk; Karadağ, Aytaç; Kılıç, Leyla; Erten, Nilgün; Taşçıoğlu, Cemil; Omer, Beyhan

doi:10.5505/tjb.2013.75437

Cited by 2 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TXB 2 is the metabolite of TXA 2 a vasoconstrictor and a platelet coagulant ( 21 ) and therefore a direct measure of the pharmacological effect of ASA. TXB 2 measurements allow determination of an individual responsiveness to ASA ( 22 ). In our study, the level of TXB 2 dropped by 40% after six weeks on ASA, when compared to baseline level (p=0.004) and increased by 20% two weeks after the end of the treatment ( Figure 2 ).…”

Section: Resultsmentioning

confidence: 99%

Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention

et al. 2021

View full text Add to dashboard Cite

IntroductionAcetylsalicylic acid (ASA) is a well-known and safe anti-inflammatory. At low-dose, it is prescribed to prevent secondary cardiovascular events in those with pre-existing conditions and to prevent preeclampsia. Little is known about how low-dose ASA affects the immune response. In this study, we followed women to assess how ASA use modifies T cells immune phenotypes in the blood and at the genital tract.MethodsHIV uninfected women from Kenya were enrolled in this study and followed for one month to assess baseline responses including systemic/mucosal baseline immune activation. Participants then received 81mg of ASA daily for 6 weeks to assess changes to T cell immune activation (systemic and mucosal) relative to baseline levels.ResultsThe concentration of ASA measured in the blood was 58% higher than the level measured at the female genital tract. In the blood, the level of ASA was inversely correlated with the following: the proportion of Th17 expressing HLA-DR (p=0.04), the proportion of effector CD4+ T cells expressing CCR5 (p=0.03) and the proportion of CD8+Tc17 expressing CCR5 (p=0.04). At the genital tract, ASA use correlated with a decreased of activated CD4+T cells [CD4+CCR5+CD161+ (p=0.02) and CD4+CCR5+CD95+ (p=0.001)].ConclusionThis study shows that ASA use impacts the immune response in both the systemic and genital tract compartments. This could have major implications for the prevention of infectious diseases such as HIV, in which the virus targets activated T cells to establish an infection. This could inform guidelines on ASA use in women.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT02079077.

show abstract

Section: Resultsmentioning

confidence: 99%